Literature DB >> 22219150

Radioisotope therapy of bone metastases.

Maciej Bączyk1.   

Abstract

Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and disseminated cancer for 50 years. Specific radioisotopes (b- or a-emitters) with selective concentration at sites of bone cancer damage are used in the treatment. Radioisotopes are an important addition to the armamentarium of clinicians who take care of patients with advanced cancer and painful cancer bone metastases (especially osteoblastic and mixed type). They offer a high degree of efficacy with minimal toxicity and simple administration, fulfilling the fundamental criteria for palliative treatment that should combine minimal patient discomfort and toxicity with maximal clinical effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22219150     DOI: 10.5603/nmr.2011.00023

Source DB:  PubMed          Journal:  Nucl Med Rev Cent East Eur        ISSN: 1506-9680


  4 in total

Review 1.  Translational Strategies to Target Metastatic Bone Disease.

Authors:  Gabriel M Pagnotti; Trupti Trivedi; Khalid S Mohammad
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

Review 2.  The best of both worlds - managing the cancer, saving the bone.

Authors:  Issam Makhoul; Corey O Montgomery; Dana Gaddy; Larry J Suva
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

3.  Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis.

Authors:  Narjess Ayati; Kamran Aryana; Amir Jalilian; Toktam Hoseinnejad; Ali Bahrami Samani; Zahra Ayati; Farzane Shariati; S Rasoul Zakavi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013

Review 4.  The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.

Authors:  Mari I Suominen; Timothy Wilson; Sanna-Maria Käkönen; Arne Scholz
Journal:  Int J Mol Sci       Date:  2019-08-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.